Market capitalization | $335.67b |
P/E (TTM) P/E ratio | 79.23 |
P/S ratio (TTM) P/S ratio | 5.96 |
P/B ratio (TTM) P/B ratio | 55.65 |
Dividend yield | 3.31% |
Last dividend (FY24) | $6.29 |
Revenue growth (TTM) Revenue growth | 3.71% |
Revenue (TTM) Revenue | $56.33b |
EBIT (operating result TTM) EBIT | $16.68b |
As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.
31 Analysts have issued a AbbVie forecast:
31 Analysts have issued a AbbVie forecast:
Dec '24 |
+/-
%
|
||
Revenue | 56,334 56,334 |
4%
4%
|
|
Gross Profit | 47,609 47,609 |
25%
25%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 16,678 16,678 |
17%
17%
|
Net Profit | 4,248 4,248 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Head office | United States |
CEO | Robert Michael |
Founded | 2011 |
Website | www.abbvie.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.